Jefferies Financial Group set a €47.00 ($54.65) target price on Fresenius SE & Co KGaA (FRA:FRE) in a report issued on Friday morning. The brokerage currently has a neutral rating on the stock.

Several other research firms also recently issued reports on FRE. Deutsche Bank set a €85.00 ($98.84) price target on Fresenius SE & Co KGaA and gave the company a buy rating in a research note on Friday, October 5th. Warburg Research set a €80.00 ($93.02) price target on Fresenius SE & Co KGaA and gave the company a buy rating in a research note on Thursday, October 4th. Kepler Capital Markets set a €82.00 ($95.35) price target on Fresenius SE & Co KGaA and gave the company a buy rating in a research note on Tuesday, October 2nd. Commerzbank set a €83.00 ($96.51) price target on Fresenius SE & Co KGaA and gave the company a buy rating in a research note on Tuesday, October 2nd. Finally, Independent Research set a €80.00 ($93.02) price target on Fresenius SE & Co KGaA and gave the company a buy rating in a research note on Tuesday, October 2nd. Nine analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. Fresenius SE & Co KGaA has an average rating of Buy and an average target price of €63.12 ($73.40).

Shares of FRE traded down €1.20 ($1.40) during midday trading on Friday, hitting €43.02 ($50.02). The stock had a trading volume of 2,038,892 shares. Fresenius SE & Co KGaA has a twelve month low of €60.16 ($69.95) and a twelve month high of €80.00 ($93.02).

Fresenius SE & Co KGaA Company Profile

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

Further Reading: Is the Dow Jones Industrial Average (DJIA) still relevant?

Analyst Recommendations for Fresenius SE & Co KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.